RACHAEL BIERSCHENK: Open Payments
NPI 1972903169 · CUMMING, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,112 in 30 payments from 9 companies in 2025. Trend: 2023 $802 · 2024 $1,156 · 2025 $1,112
Food & beverage: $1,112
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $242 |
| Janssen Biotech, Inc. | 6 | $216 |
| Mallinckrodt Hospital Products Inc. | 6 | $202 |
| ABBVIE INC. | 9 | $141 |
| Ardelyx, Inc. | 2 | $138 |
| Ipsen Biopharmaceuticals, Inc | 1 | $66 |
| GENZYME CORPORATION | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
Products named: TREMFYA, TERLIVAZ, IBSRELA, Vemlidy, Livdelzi, RINVOQ, DUPIXENT, IQIRVO.
Industry payments across GA — which companies pay providers there.
